Novartis AG (0QLR)

74.75
-1.50(-1.97%)
  • Volume:
    1,337,119
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    74.75 - 74.75

0QLR Overview

Prev. Close
76.25
Day's Range
74.75-74.75
Revenue
-
Open
75.25
52 wk Range
66.14-86.93
EPS
-
Volume
1,337,119
Market Cap
167.16B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
959,096
P/E Ratio
18.87
Beta
-
1-Year Change
-7.66%
Shares Outstanding
2,237,091,519
Next Earnings Date
-
What is your sentiment on Novartis AG?
or
Market is currently closed. Voting is open during market hours.

Novartis AG Company Profile

Employees
108000

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsBuyStrong SellStrong SellStrong SellStrong Sell
SummaryNeutralStrong SellStrong SellStrong SellStrong Sell
  • Hi Guys, I have been invested in Novartis for 5 years and have closely followed the pharmaceutical industry for years. I have been very disappointed with the returns and am looking to transfer my portfolio into riskier assets. Upon research, I think I may have found an even better pharmaceutical company going by the name of SpectrumX. SpectrumX are leaders in patented shielded HOCL formulations that have numerous applications in medical/pharma fields. They have also undergone 2 clinical trials for Covid-19 treatment (apparently not factored into the company valuation.) To me this company seems to be on track for high growth after the IPO, however I may be getting lost in the hype. Would love to hear people's thoughts on the stock as I am keen to invest early.
    0
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.